IP Library › Granted Patent US 12,208,385
Granted Patent B2
US 12,208,385 · App. 17/700,031 · Granted Jan 28, 2025

Systems and methods for fabricating microfluidic devices

Inventors: Ashley Lynne Beckwith (Cambridge, MA); Jeffrey Borenstein (Newton, MA); Nathan Moore (Canton, MA); Daniel Doty (Arlington, MA); Luis Velásquez-García (Cambridge, MA)
Assignees: The Charles Draper Laboratory, Inc.; Massachusetts Institute of Technology
B01L3/502707B29C64/135B29C64/393B81C1/00071B01L2200/12B33Y10/00B33Y80/00B81B2201/058B81B2203/0338Y10T428/24744
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,208,385
App. No.
17/700,031
Granted
Jan 28, 2025
Kind
B2
Abstract

This disclosure describes techniques for fabricating a high-resolution, non-cytotoxic and transparent microfluidic device. A material can be selected based on having an optical property with a predetermined degree of transparency to provide viewability of a biological sample through the microfluidic device and a level of cytotoxicity within a predetermined threshold to provide viability of the biological sample within the microfluidic device. An additive manufacturing technique can be selected from a plurality of additive manufacturing techniques for fabricating the microfluidic device based on the selected material to provide a resolution of dimensions of one or more channels of the microfluidic device higher than a predetermined resolution threshold.

Claims (23)

1. A device comprising:

a construction comprising one or more channels having a resolution of dimensions higher than a threshold of less than 100, 150, 200 or 250 microns;

wherein the device is constructed using an additive manufacturing technique selected to provide the resolution of dimensions of the one or more channels higher than the threshold of less than 100, 150, 200 or 250 microns;

wherein a material used to construct the device provides for non-cytotoxicity over an extended period of time, optical transparency to visible light, reduced auto-fluorescence to enable data capture of the device operation via fluorescent images, and fabrication to reproduce features of less than 100 microns; and

wherein the material comprises at least 50%, or 60% or 70% by weight of polyethyl methacrylate polymer or copolymer.

2. The device of claim 1 , wherein the construction is a single piece or one piece construction.

3. The device of claim 1 , wherein the additive manufacturing technique is applied according to a parameter for layer thickness and a parameter for curing thickness offset in the range of about 0.01 millimeters to about 0.3 millimeters.

4. The device of claim 1 , wherein the additive manufacturing technique is one of 3D printing, stereolithography (SLA) or digital light projection stereolithography (SLA-DLP).

5. The device of claim 1 , wherein the one or more channels have a height in the range of about 0.01 millimeters to about 2.5 millimeters and a width in the range of about 0.01 millimeters to about 2.5 millimeter.

6. The device of claim 1 , wherein the material provided for survival of at least 90% of cells included in a biological sample over a period of at least one week.

7. The device of claim 1 , wherein the construction further comprises one or more bubble traps or one or more resistance lines.

8. A device comprising:

a construction comprising one or more channels having a resolution of dimensions higher than a threshold of less than 100, 150, 200 or 250 microns;

wherein the device is constructed using an additive manufacturing technique selected to provide the resolution of dimensions of the one or more channels higher than the threshold of less than 100, 150, 200 or 250 microns;

wherein the device is constructed by sequentially applying the additive manufacturing technique to a material to create a plurality of layers of the device, based on a model for the device specifying a plurality of parameters;

wherein the material used to construct the device provides for non-cytotoxicity over an extended period of time, optical transparency to visible light, reduced auto-fluorescence to enable data capture of the device operation via fluorescent images, and fabrication to reproduce features of less than 100 microns; and

wherein the material includes at least 50%, or 60% or 70% by weight of polyethyl methacrylate polymer or copolymer.

9. The device of claim 8 , wherein the construction is a single piece or one piece construction.

10. The device of claim 8 , wherein the plurality of parameters comprises a parameter for layer thickness and a predetermined parameter for curing thickness offset in the range of about 0.01 millimeters to about 0.3 millimeters.

11. The device of claim 8 , wherein the material comprises a polymer selected from a group consisting of polyetheretherketone (“PEEK”), polymethylacrylamide or polyacrylamide, polyvinylalcohol, polycaprolactone and polylactide.

12. The device of claim 8 , wherein the additive manufacturing technique is one of 3D printing, stereolithography (SLA) or digital light projection stereolithography (SLA-DLP).

13. The device of claim 8 , wherein the one or more channels have a height in the range of about 0.01 millimeters to about 2.5 millimeters and a width in the range of about 0.01 millimeters to about 2.5 millimeter.

14. The device of claim 8 , wherein the material provides for survival of at least 90% of cells included in a biological sample over a period of at least one week.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2023
From: BECKWITH, ASHLEY; BORENSTEIN, JEFFREY; MOORE, NATHAN; DOTY, DANIEL
To: THE CHARLES STARK DRAPER LABORATORY, INC.
Reel/Frame 064148/0932 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2023
From: GARCIA, LUIS VELASQUES
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 064149/0023 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2023
From: TANDON, VISHAL; PEPPI, MARCELLO
To: THE CHARLES STARK DRAPER LABORATORY, INC.
Reel/Frame 062343/0582 →
Continuity (5)
Continuation 16116637 · Aug 29, 2018
Provisional Application 62649016 · Mar 28, 2018
Provisional Application 62611513 · Dec 28, 2017
Provisional Application 62552267 · Aug 30, 2017
Related Publication 20220280936A1 · Sep 8, 2022
References Cited (15)
US 6136212A · Mastrangelo et al. · 2000 [cited by applicant]
US 11278885B2 · Beckwith · 2022 [cited by examiner]
US 20040069717A1 · Laurell et al. · 2004 [cited by applicant]
US 20070281353A1 · Vacanti · 2007 [cited by examiner]
US 20140030788A1 · Chen et al. · 2014 [cited by applicant]
EP 1451568A2 · 2004 [cited by applicant]
WO WO2008069761A1 · 2008 [cited by examiner]
WO WO2017027838A1 · 2017 [cited by applicant]
WO WO2017089963A1 · 2017 [cited by applicant]
International Preliminary Report of Patentability on PCT PCT/US2018/048591 Dtd Mar. 12, 2020. [cited by applicant]
International Search Report for PCT/US2018/048591 Dtd Oct. 16, 2018; 4 pages. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 16/116,637 DTD May 12, 2021. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 16/116,637 DTD Oct. 29, 2020. [cited by applicant]
Notice of Allowance on U.S. Appl. No. 16/116,637 DTD Nov. 2, 2021. [cited by applicant]
Office Action issued in corresponding European Patent Application No. 18766532.8 dated Mar. 6, 2024 (6 pages). [cited by applicant]